Furthermore, the difference between 1- and 3- year overall survival and progression-free survival was comparable by analyzing studies with a rate > 20% of PD-L1 < 1% and with a rate > 75% of adenocarcinoma. The gene discussed is CD274; the disease is adenocarcinoma.